An Open-label, Phase I/Proof of Principle, Dose Escalation Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation (PCI) of Antigen/Adjuvant in Healthy Male/Female Subjects

Trial Profile

An Open-label, Phase I/Proof of Principle, Dose Escalation Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation (PCI) of Antigen/Adjuvant in Healthy Male/Female Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2016

At a glance

  • Drugs Fimaporfin (Primary) ; Human papillomavirus E7 protein modulators; Keyhole limpet haemocyanin; Poly ICLC
  • Indications Cholangiocarcinoma; Malignant melanoma
  • Focus Adverse reactions; Proof of concept
  • Sponsors PCI Biotech
  • Most Recent Events

    • 04 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top